Antagonism of Vasopressin-Induced Coronary Artery Constriction by the Vasopressin Antagonist d(CH2)5Tyr(Me)-AVP
| Autor: | G A Kopia, Richard E. Valocik |
|---|---|
| Rok vydání: | 1985 |
| Předmět: |
Vasopressin
medicine.medical_specialty Vasopressins Hemodynamics Blood Pressure Electrocardiography Coronary circulation Dogs Heart Rate Coronary Circulation Internal medicine Animals Medicine Pharmacology Dose-Response Relationship Drug business.industry Blood flow Coronary Vessels Arginine Vasopressin Mean blood pressure Blood pressure medicine.anatomical_structure Vasoconstriction Anesthesia Cardiology medicine.symptom Cardiology and Cardiovascular Medicine business hormones hormone substitutes and hormone antagonists Artery |
| Zdroj: | Journal of Cardiovascular Pharmacology. 7:958-963 |
| ISSN: | 0160-2446 |
| Popis: | d(CH2)5Tyr(Me)-AVP is a potent inhibitor of the systemic vasoconstrictor action of vasopressin (AVP). In order to examine the effectiveness of this agent in blocking AVP-induced coronary vasoconstriction, 11 pentobarbital-anesthetized mongrel dogs were instrumented for the measurement of left circumflex (LCX) coronary blood flow, systemic arterial blood pressure, heart rate, lead II electrocardiogram, left ventricular end-diastolic pressure, left ventricular developed pressure, and left ventricular +/- dP/dt. Direct injection of AVP (0.01-1 microgram) into the LCX produced a dose-dependent decrease in coronary artery blood flow (maximum reduction: 60.5 +/- 8.1% after 1 microgram), - dP/dt (maximum reduction: 41.8 +/- 5.3% after 1 microgram), and +dP/dt (maximum reduction: 14.6 +/- 5.3%), whereas a dose-dependent increase in left ventricular end-diastolic pressure was observed (maximum increase: 62.6 +/- 20.2%). No significant changes occurred in heart rate, mean blood pressure, or left ventricular developed pressure. Intravenous administration of d(CH2)5Tyr(Me)-AVP reduced (1 microgram/kg) or abolished (5 micrograms/kg) the effects of AVP on coronary blood flow +/-dP/dt and left ventricular end-diastolic pressure. In addition, doses of 1,2, and 5 micrograms/kg of d(CH2)5Tyr(Me)-AVP alone produced increases of LCX blood flow of 5.1 +/- 1.5, 2.0 +/- 0.7, and 6.8 +/- 1.7 ml/min, respectively (p less than 0.05). We conclude that d(CH2)5Tyr(Me)-AVP is effective in preventing the coronary artery constriction and hemodynamic sequelae of intracoronary administered AVP. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|